On Wednesday, BioMed Realty, a company within the Blackstone portfolio, announced that it has signed a lease amendment with Xaira Therapeutics. This leading AI-driven drug discovery company will be expanding its headquarters from 56,233 square feet to 73,075 square feet at BioMed Realty’s Gateway of Pacific III campus in South San Francisco.
According to BioMed Realty representatives, this expansion is a result of the increasing demand for high-quality life science facilities in the Bay Area and supports Xaira’s rapid growth as an AI-driven drug discovery leader. The new space will serve as an essential foundation for advancing their machine-learning research and therapeutic product development while reinforcing the Bay Area’s reputation as a global hub for biotech and technology innovation.
Uplaksh Kumar from Xaira expressed excitement about their new facility at Gateway of Pacific III campus by stating that it provides them with collaborative and inviting space to focus on groundbreaking work using AI technology. He also believes that this move has potential to revolutionize drug development processes.
